Scientific Opinion on the substantiation of health claims related to konjac mannan (glucomannan) and reduction of body weight (ID 854, 1556, 3725), reduction of post-prandial glycaemic responses (ID 1559), maintenance of normal blood glucose concentrations (ID 835, 3724), maintenance of normal (fasting) blood concentrations of triglycerides (ID 3217), maintenance of normal blood cholesterol concentrations (ID 3100, 3217), maintenance of normal bowel function (ID 834, 1557, 3901) and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 1558) pursuant to Article 13(1) of Regulation (EC) No 1924/2006: EFSA-Q-2008-1621 , EFSA-Q-2008-1622 , EFSA-Q-2008-1641 , EFSA-Q-2008-2293 , EFSA-Q-2008-2294 , EFSA-Q-2008-2295 , EFSA-Q-2008-2296 , EFSA-Q-2008-3832 , EFSA-Q-2008-3949 , EFSA-Q-2008-4446 , EFSA-Q-2008-4447 , EFSA-Q-2008-4617

Inge Tetens

Research output: Book/ReportReportResearchpeer-review

Original languageEnglish
PublisherEuropean Food Safety Authority
Publication statusPublished - 2010

Keywords

  • blood glucose
  • potentially pathogenic organisms
  • glycaemic control
  • weight management
  • konjac mannan
  • health claims
  • bowel function
  • blood lipids
  • intestinal transit
  • body weight
  • glucomannan

Cite this